A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
Status:
Recruiting
Trial end date:
2025-02-06
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics
(PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731
administered as a monotherapy in participants with newly diagnosed or recurrent epidermal
growth factor receptor variant III (EGFRvIII)-positive glioblastoma (GBM).